Literature DB >> 15111337

Fatigue in cancer patients receiving chemotherapy: an analysis of published studies.

A Iop1, A M Manfredi, S Bonura.   

Abstract

Fatigue is a subjective experience that affects everybody. In healthy individuals, it can be considered a physiological response to physical or psychological stress. In people with specific diseases, however, fatigue often represents one of the most significant problems. Fatigue can be caused by many factors, both intrinsic to the patient and extrinsic, such as therapeutic interventions. This review, based on published studies, has been conducted with the aim of presenting a critical discussion of the available information on the characteristics, causes and potential treatments of fatigue in cancer patients receiving chemotherapy. The incidence of fatigue in these patients, the methods for measuring and evaluating fatigue, and possible therapeutic options are discussed. An appraisal of the toxicity of various chemotherapeutic agents is also presented. Although fatigue is now an ever more considered aspect of the toxicity of chemotherapy, it remains difficult to establish what standard should be used to make a quali-quantitative evaluation of this symptom. Furthermore, in the absence of a clear demonstration of the efficacy of some therapies, the management of cancer-related fatigue remains poorly defined (except for the treatment of anemia-related fatigue). New randomized clinical trials are necessary to indicate the best strategies for tackling this important problem.

Entities:  

Mesh:

Year:  2004        PMID: 15111337     DOI: 10.1093/annonc/mdh102

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  22 in total

Review 1.  ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials.

Authors:  Andrea M Barsevick; Charles S Cleeland; Donald C Manning; Ann M O'Mara; Bryce B Reeve; Jane A Scott; Jeff A Sloan
Journal:  J Pain Symptom Manage       Date:  2010-06       Impact factor: 3.612

2.  Effectiveness of a clinical intervention to eliminate barriers to pain and fatigue management in oncology.

Authors:  Tami Borneman; Marianna Koczywas; Virginia Sun; Barbara F Piper; Cynthia Smith-Idell; Benjamin Laroya; Gwen Uman; Betty Ferrell
Journal:  J Palliat Med       Date:  2011-01-27       Impact factor: 2.947

3.  Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.

Authors:  Elizabeth Hovey; Paul de Souza; Gavin Marx; Phillip Parente; Tal Rapke; Andrew Hill; Antonino Bonaventura; Antony Michele; Paul Craft; Ehtesham Abdi; Andrew Lloyd
Journal:  Support Care Cancer       Date:  2013-12-17       Impact factor: 3.603

4.  Quality of life and barriers to symptom management in colon cancer.

Authors:  Virginia Sun; Tami Borneman; Marianna Koczywas; Mihaela Cristea; Barbara F Piper; Gwen Uman; Betty Ferrell
Journal:  Eur J Oncol Nurs       Date:  2011-07-23       Impact factor: 2.398

5.  Methylphenidate for fatigue in ambulatory men with prostate cancer.

Authors:  Andrew J Roth; Christian Nelson; Barry Rosenfeld; Howard Scher; Susan Slovin; Michael Morris; Noelle O'Shea; Gabrielle Arauz; William Breitbart
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

6.  Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial.

Authors:  Gary Deng; Yi Chan; Daniel Sjoberg; Andrew Vickers; K Simon Yeung; Mark Kris; David Straus; Barrie Cassileth
Journal:  Support Care Cancer       Date:  2013-01-20       Impact factor: 3.603

7.  Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer.

Authors:  Masahide Ikeguchi; Manabu Yamamoto; Yosuke Arai; Yoshihiko Maeta; Keigo Ashida; Kuniyuki Katano; Yasunari Miki; Takayuki Kimura
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

Review 8.  A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies.

Authors:  Ilufredo Y Tantoy; Janine K Cataldo; Bradley E Aouizerat; Anand Dhruva; Christine Miaskowski
Journal:  Cancer Nurs       Date:  2016 Nov-Dec       Impact factor: 2.760

9.  Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.

Authors:  James M G Larkin; Lynda M Pyle; Martin E Gore
Journal:  Oncologist       Date:  2010-11-04

10.  Validation of a questionnaire measuring the regulation of autonomic function.

Authors:  M Kröz; G Feder; Hb von Laue; R Zerm; M Reif; M Girke; H Matthes; C Gutenbrunner; C Heckmann
Journal:  BMC Complement Altern Med       Date:  2008-06-05       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.